Streetbeat News

Regulatory

NVO

Novo Nordisk's Ozempic has shown promising results in a late-stage trial, slowing the worsening of kidney dysfunction and lowering the risk of kidney failure, heart problems, stroke, and death in type 2 diabetes patients.

Portfolio Pulse from Charles Gross

May 24, 2024 | 10:36 am

OGN

Organon announced that the European Medicines Agency (EMA) has validated the marketing authorization applications for HLX14, a biosimilar candidate for Prolia and Xgeva (denosumab). This biosimilar targets the treatment of osteoporosis, a condition affecting millions in Europe.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 10:03 am

BTCUSD

ETHUSD

The SEC has approved the first Ethereum spot ETFs in the U.S., which could lead to a 60% surge in Ethereum's value, according to QCP Capital. This approval is expected to bring significant changes to the cryptocurrency market, including increased mainstream investor access and potential political implications.

Portfolio Pulse from Benzinga Neuro

May 24, 2024 | 9:26 am

AMZN

TSLA

Elon Musk highlighted that Tesla has built more EV charging infrastructure in the U.S. than Amazon and the federal government. Tesla has over 2,200 public supercharger locations with nearly 26,000 charging ports in the U.S., while Amazon has installed 17,000 chargers at its warehouses. The federal government lags significantly behind with only 41 station locations and 80 EV charging ports.

Portfolio Pulse from Anan Ashraf

May 24, 2024 | 8:26 am

Singapore Airlines has revised its seatbelt sign policies and changed the flight route of SQ321 after a deadly turbulence incident. The incident involved a Boeing 777-300ER and resulted in one fatality and multiple injuries.

Portfolio Pulse from Benzinga Neuro

May 24, 2024 | 8:13 am

ARKK

BEN

BITW

BLK

FDX

GBTC

IVZ

VAN

SEC Chair Gary Gensler did not participate in the decision to approve the first-ever spot Ethereum ETFs in the U.S. The SEC’s Trading and Markets Division approved the forms for several spot Ethereum ETFs from companies like BlackRock, Fidelity, and Grayscale. This decision was made under delegated authority, unlike the approval process for spot Bitcoin ETFs, which involved a vote by the commissioners.

Portfolio Pulse from Aniket Verma

May 24, 2024 | 6:40 am

Guardant Health's Shield blood test for colorectal cancer screening has received a strong recommendation from the FDA advisory committee, paving the way for potential FDA approval. This test offers a convenient, non-invasive screening option and is on track to become the first FDA-approved blood test meeting Medicare coverage requirements.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 6:37 am

GOOG

GOOGL

Google's new AI Overviews feature, part of its Search Generative Experience, has faced backlash for providing inaccurate and sometimes absurd responses. Notable errors include suggesting glue to keep cheese on pizza and incorrectly stating that Barack Obama was the first Muslim President of the U.S. Google has acknowledged these issues and is working to improve the product.

Portfolio Pulse from Ananya Gairola

May 24, 2024 | 6:13 am

NVDA

Nvidia has reduced the prices of its H20 AI chips in China by over 10% to compete with Huawei's Ascend 910B amid increased competition and U.S. sanctions. This move highlights the challenges Nvidia faces in the Chinese market, which contributed 17% of its revenue for fiscal 2024. Despite these challenges, Nvidia continues to adapt its strategy to maintain its presence in China.

Portfolio Pulse from Benzinga Neuro

May 24, 2024 | 6:03 am

HCM

HUTCHMED will present new and updated data from several studies at ASCO 2024, including a Phase II study of fruquintinib combined with sintilimab in endometrial cancer patients. The study showed significant efficacy improvements and a manageable safety profile, supporting a New Drug Application in China.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 5:51 am